Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations

1
Asthma Therapeutics in Major Developed Markets to
2020 - Personalized Treatment for Severe Asthma
to Drive Market Growth despite Patent Expirations
Single User License - 3,246.75 Site User
License - 6,493.50 Corporate User License -
9,740.25 Publication Date - Feb 2015 Pages -
142 To know more details, email to
debora_at_reportstack.com
2
Summary

• The asthma therapeutics market is forecast to
  grow marginally over the forecast period across
  the top eight developed nations, from 18.4
  billion in 2013 to a projected value of 21.7
  billion by 2020 at a Compound Annual Growth Rate
  (CAGR) of 2.4. This is in spite of generic
  erosion facing several of the leading asthma
  brands, such as Advair (fluticasone
  propionate/salmeterol xinafoate), Symbicort
  (budesonide/formoterol fumarate) and Xolair
  (omalizumab), and is a consequence of new market
  entrants and rising disease prevalence.
• Although the majority of asthma patients are able
  to manage their symptoms effectively using
  currently marketed products, some remain
  inadequately controlled with these same products.
  This unmet need, coupled with rising global
  prevalence, has resulted in strong industry
  interest.

3
Scope
- An introduction to asthma, including discussion
of disease epidemiology, etiology
pathophysiology, symptoms, diagnosis, and
treatment, with clinical data for drugs featured
in the current treatment algorithm discussed in
detail- In-depth analysis of the current
marketed products landscape, including product
profiles of the main drugs used and heat maps
that compare their safety and efficacy
parameters- Comprehensive analysis of the asthma
pipeline by phase of development, molecule type,
and molecular target and novelty, and comparative
analysis of the most promising late-stage
pipeline drugs, as well as heat maps and a
competitor matrix that compares safety and
efficacy parameters- Additional in-depth
analysis of the asthma clinical trials landscape,
including trends in size, duration and failure
rate
4
Key Benefits
- Gain a comprehensive understanding of asthma,
including diagnosis, disease severity, and
treatment algorithms- Understand the current
asthma marketed products landscape and recognize
the dominant therapeutic agents and
pharmaceutical players involved- Identify
trends, developments, and prominent molecule
types and molecular targets within the asthma
pipeline- Gain an appreciation of the clinical
and commercial aspects of the most promising
late-stage pipeline molecules and their potential
competitive impact on the future market-
Consider market opportunities and potential risks
by examining trends in asthma clinical trial
size, duration and failure rate, phase of
development, molecule type, and molecular target
5
If you are interested...
Contact Debora White Email
debora_at_reportstack.com Ph1-888-789-6604 http/
/www.reportstack.com